Symbols / BGLC
BGLC Chart
About
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; and Investment Holding. It offers various chemical raw material products, including polyester resin SHCP 268, a thixotropic, quick-curing unsaturated polyester resin suitable as a general-purpose resin; polyester resin 9509, a general-purpose material used in the production of marine boats and water slides; and polyester resin 2802, which is used as a component in the pultrusion process. The company's products are used in producing various finished goods, such as handrails, bench tops, and automotive and aero parts; paneling for hospital, laboratory, and industrial clean rooms; and covers for various instruments used in manufacturing. It also develops and provides non-invasive liquid biopsy tests for the early detection of biomarkers. BioNexus Gene Lab Corp. was incorporated in 2017 and is based in Kuala Lumpur, Malaysia.
Fundamentals
Scroll to Statements| Sector | Basic Materials | Industry | Specialty Chemicals | Market Cap | 5.98M |
| Enterprise Value | 1.88M | Income | -2.30M | Sales | 9.47M |
| Book/sh | 3.79 | Cash/sh | 1.61 | Dividend Yield | — |
| Payout | 0.00% | Employees | 30 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | 0.63 | P/B | 0.67 | P/C | — |
| EV/EBITDA | -0.81 | EV/Sales | 0.20 | Quick Ratio | 6.81 |
| Current Ratio | 8.30 | Debt/Eq | 3.43 | LT Debt/Eq | — |
| EPS (ttm) | -1.28 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | -3.30% | Earnings | — | ROA | -16.43% |
| ROE | -28.35% | ROIC | — | Gross Margin | 14.77% |
| Oper. Margin | -30.26% | Profit Margin | -24.27% | Shs Outstand | 2.36M |
| Shs Float | 1.29M | Short Float | 0.88% | Short Ratio | 0.66 |
| Short Interest | — | 52W High | 15.60 | 52W Low | 1.92 |
| Beta | 2.29 | Avg Volume | 88.09K | Volume | 2.15K |
| Target Price | — | Recom | None | Prev Close | $2.38 |
| Price | $2.53 | Change | 6.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.57
Latest analyst target
3. DCF / Fair value
$-15.40
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.57
Low
—
High
—
Mean
—
- Chemrex board cut to two as BioNexus weighs new growth options - Stock Titan Mon, 23 Feb 2026 13
- BGLC Stock Tumbled Over 13% Today: Why Is VitaGuard Commercialization Agreement Drawing Investor Attention? - Stocktwits Wed, 12 Nov 2025 14
- BioNexus Gene Lab Corp. (Nasdaq: BGLC) Announces Strategic Agreements with Fidelion Diagnostics for Southeast Asia MRD Commercialization - Yahoo Finance Wed, 12 Nov 2025 08
- What’s next for BGLC stock - Analyst Upgrade & Low Risk High Reward Ideas - mfd.ru Fri, 20 Feb 2026 22
- BioNexus Gene Lab stock falls after securing $500M equity facility - Investing.com ue, 02 Dec 2025 08
- Can BioNexus Gene Lab Stock Recover If Markets Fall? - Trefis Fri, 28 Nov 2025 08
- BioNexus Gene Lab Corp. Completes Strategic Transaction with Fidelion Diagnostics, Securing Exclusive Rights for VitaGuardâ„¢ in Southeast Asia - Quiver Quantitative Wed, 03 Dec 2025 08
- BioNexus Surge: An Unexpected Market Uprising? - StocksToTrade ue, 01 Jul 2025 07
- symbol__ Stock Quote Price and Forecast - CNN hu, 15 Feb 2024 22
- Revolutionary Cancer Detection Tech Cuts Testing Costs 90% Through BioNexus-Fidelion Alliance | BGLC Stock News - Stock Titan Wed, 30 Jul 2025 07
- BioNexus Gene Lab stock climbs after securing $500 million equity facility - Investing.com ue, 02 Dec 2025 08
- BGLC Stock Price and Chart — NASDAQ:BGLC - TradingView hu, 20 Jul 2023 18
- BioNexus Gene Lab secures $500 million equity purchase agreement - Investing.com ue, 02 Dec 2025 08
- BGLC Stock Price, News & Analysis | Bionexus Gene La - Stock Titan hu, 24 Apr 2025 17
- BioNexus Gene Lab Corp. Regains Compliance with Nasdaq Listing Rule and Enhances Growth Strategy - Quiver Quantitative Wed, 30 Apr 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 42.24K | 90.06K | 0.00 | 0.00 |
| TaxRateForCalcs | 0.24 | 0.24 | 0.24 | 0.28 |
| NormalizedEBITDA | -1.60M | -2.86M | -185.76K | 1.16M |
| TotalUnusualItems | 176.01K | 375.27K | ||
| TotalUnusualItemsExcludingGoodwill | 176.01K | 375.27K | ||
| NetIncomeFromContinuingOperationNetMinorityInterest | -1.60M | -2.63M | -355.97K | 751.57K |
| ReconciledDepreciation | 153.14K | 108.42K | 105.42K | 108.22K |
| ReconciledCostOfRevenue | 8.22M | 8.44M | 9.67M | 11.10M |
| EBITDA | -1.42M | -2.49M | -185.76K | 1.16M |
| EBIT | -1.57M | -2.59M | -291.18K | 1.06M |
| NetInterestIncome | 126.50K | 54.75K | -12.48K | -12.97K |
| InterestExpense | 21.15K | 13.93K | 12.48K | 12.97K |
| InterestIncome | 147.64K | 68.67K | ||
| NormalizedIncome | -1.73M | -2.91M | -355.97K | 751.57K |
| NetIncomeFromContinuingAndDiscontinuedOperation | -1.60M | -2.63M | -355.97K | 751.57K |
| TotalExpenses | 11.47M | 12.85M | 11.22M | 12.31M |
| TotalOperatingIncomeAsReported | -1.57M | -2.59M | -291.18K | 1.06M |
| DilutedAverageShares | 1.78M | 1.59M | 1.44M | 1.43M |
| BasicAverageShares | 1.78M | 1.59M | 1.44M | 1.43M |
| DilutedEPS | -0.90 | -1.66 | -0.46 | 0.48 |
| BasicEPS | -0.90 | -1.66 | -0.46 | 0.48 |
| DilutedNIAvailtoComStockholders | -1.60M | -2.63M | -355.97K | 751.57K |
| NetIncomeCommonStockholders | -1.60M | -2.63M | -355.97K | 751.57K |
| NetIncome | -1.60M | -2.63M | -355.97K | 751.57K |
| NetIncomeIncludingNoncontrollingInterests | -1.60M | -2.63M | -355.97K | 751.57K |
| NetIncomeContinuousOperations | -1.60M | -2.63M | -355.97K | 751.57K |
| TaxProvision | 3.49K | 21.53K | 52.31K | 291.28K |
| PretaxIncome | -1.59M | -2.61M | -303.66K | 1.04M |
| OtherIncomeExpense | 235.42K | 417.36K | ||
| OtherNonOperatingIncomeExpenses | 59.41K | 42.09K | ||
| GainOnSaleOfSecurity | 176.01K | 375.27K | ||
| NetNonOperatingInterestIncomeExpense | 126.50K | 54.75K | -12.48K | -12.97K |
| InterestExpenseNonOperating | 21.15K | 13.93K | 12.48K | 12.97K |
| InterestIncomeNonOperating | 147.64K | 68.67K | ||
| OperatingIncome | -1.96M | -3.08M | -291.18K | 1.06M |
| OperatingExpense | 3.25M | 4.41M | 1.55M | 1.21M |
| OtherOperatingExpenses | -486.04K | -179.28K | -66.49K | |
| ProvisionForDoubtfulAccounts | -805.88K | 1.31M | ||
| ResearchAndDevelopment | 47.51K | 54.98K | ||
| SellingGeneralAndAdministration | 4.00M | 3.04M | 1.73M | 1.28M |
| SellingAndMarketingExpense | 2.03M | 596.86K | ||
| GeneralAndAdministrativeExpense | 1.97M | 2.44M | 1.73M | 1.28M |
| OtherGandA | 1.97M | 2.44M | 1.73M | 1.28M |
| GrossProfit | 1.29M | 1.33M | 1.26M | 2.27M |
| CostOfRevenue | 8.22M | 8.44M | 9.67M | 11.10M |
| TotalRevenue | 9.51M | 9.77M | 10.93M | 13.36M |
| OperatingRevenue | 9.51M | 9.77M | 10.93M | 13.36M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 1.80M | 1.77M | 1.45M | 1.43M |
| ShareIssued | 1.80M | 1.77M | 1.45M | 1.43M |
| TotalDebt | 210.56K | 133.40K | 56.77K | 76.95K |
| TangibleBookValue | 8.32M | 9.66M | 6.67M | 7.18M |
| InvestedCapital | 8.32M | 9.66M | 6.67M | 7.18M |
| WorkingCapital | 5.48M | 6.42M | 4.02M | 4.82M |
| NetTangibleAssets | 8.32M | 9.66M | 6.67M | 7.18M |
| CapitalLeaseObligations | 210.56K | 133.40K | 56.77K | 76.95K |
| CommonStockEquity | 8.32M | 9.66M | 6.67M | 7.18M |
| TotalCapitalization | 8.32M | 9.66M | 6.67M | 7.18M |
| TotalEquityGrossMinorityInterest | 8.32M | 9.66M | 6.67M | 7.18M |
| StockholdersEquity | 8.32M | 9.66M | 6.67M | 7.18M |
| GainsLossesNotAffectingRetainedEarnings | -555.00K | -677.29K | -409.06K | -100.26K |
| OtherEquityAdjustments | -555.00K | -677.29K | -409.06K | -100.26K |
| RetainedEarnings | -3.44M | -1.84M | 1.16M | 1.51M |
| AdditionalPaidInCapital | -5.01M | -5.01M | -5.01M | -5.01M |
| CapitalStock | 17.33M | 17.19M | 10.93M | 10.78M |
| CommonStock | 17.33M | 17.19M | 10.93M | 10.78M |
| TotalLiabilitiesNetMinorityInterest | 2.11M | 1.74M | 2.08M | 2.39M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 159.74K | 111.02K | 71.07K | 65.86K |
| NonCurrentDeferredLiabilities | 0.00 | 12.26K | 30.87K | 28.42K |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 12.26K | 30.87K | 28.42K |
| LongTermDebtAndCapitalLeaseObligation | 159.74K | 98.76K | 40.21K | 37.44K |
| LongTermCapitalLeaseObligation | 159.74K | 98.76K | 40.21K | 37.44K |
| CurrentLiabilities | 1.95M | 1.63M | 2.00M | 2.33M |
| CurrentDeferredLiabilities | 95.88K | 0.00 | 23.12K | 107.58K |
| CurrentDeferredRevenue | 95.88K | 0.00 | 23.12K | 107.58K |
| CurrentDebtAndCapitalLeaseObligation | 50.82K | 34.63K | 16.57K | 39.51K |
| CurrentCapitalLeaseObligation | 50.82K | 34.63K | 16.57K | 39.51K |
| PayablesAndAccruedExpenses | 1.80M | 1.60M | 1.96M | 2.18M |
| Payables | 1.80M | 1.60M | 1.96M | 2.18M |
| OtherPayable | 284.11K | 180.91K | 103.37K | 71.81K |
| DuetoRelatedPartiesCurrent | 17.17K | 13.20K | 0.00 | |
| TotalTaxPayable | 0.00 | 97.58K | ||
| AccountsPayable | 1.50M | 1.40M | 1.86M | 2.01M |
| TotalAssets | 10.43M | 11.40M | 8.74M | 9.57M |
| TotalNonCurrentAssets | 3.00M | 3.35M | 2.72M | 2.42M |
| InvestmentsAndAdvances | 1.27M | 1.70M | 1.15M | 749.03K |
| OtherInvestments | 1.27M | 1.70M | 1.15M | 749.03K |
| NetPPE | 1.74M | 1.65M | 1.57M | 1.68M |
| AccumulatedDepreciation | -797.15K | -659.12K | -616.91K | -525.63K |
| GrossPPE | 2.54M | 2.31M | 2.18M | 2.20M |
| ConstructionInProgress | 0.00 | 109.51K | 0.00 | |
| OtherProperties | 534.56K | 396.70K | 411.62K | 429.78K |
| MachineryFurnitureEquipment | 493.86K | 299.10K | 265.76K | 264.39K |
| Properties | 1.51M | 1.51M | 1.51M | 1.51M |
| CurrentAssets | 7.43M | 8.05M | 6.02M | 7.15M |
| CurrentDeferredAssets | 0.00 | 67.61K | ||
| Inventory | 1.39M | 1.14M | 977.81K | 1.52M |
| FinishedGoods | 1.39M | 1.14M | 977.81K | 1.52M |
| Receivables | 1.66M | 979.69K | 2.93M | 3.44M |
| OtherReceivables | 203.66K | 122.43K | 25.24K | 79.52K |
| TaxesReceivable | 84.17K | 57.59K | 31.55K | 0.00 |
| AccountsReceivable | 1.38M | 799.67K | 2.87M | 3.36M |
| AllowanceForDoubtfulAccountsReceivable | -517.88K | -1.31M | -12.60K | -3.81K |
| GrossAccountsReceivable | 1.89M | 2.11M | 2.87M | 3.36M |
| CashCashEquivalentsAndShortTermInvestments | 4.38M | 5.93M | 2.12M | 2.12M |
| CashAndCashEquivalents | 4.38M | 5.93M | 2.12M | 2.12M |
| CashEquivalents | 2.79M | 3.31M | 1.51M | 1.55M |
| CashFinancial | 1.58M | 2.62M | 611.85K | 578.51K |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -2.46M | -1.97M | 497.65K | 6.00K |
| RepaymentOfDebt | 0.00 | -34.04K | -26.30K | |
| IssuanceOfCapitalStock | 150.00K | 0.00 | ||
| CapitalExpenditure | -226.99K | -149.40K | -54.17K | -3.16K |
| InterestPaidSupplementalData | 9.35K | 8.88K | 12.48K | 12.97K |
| IncomeTaxPaidSupplementalData | 40.38K | 66.97K | 170.45K | 226.77K |
| EndCashPosition | 2.89M | 4.52M | 2.12M | 2.12M |
| BeginningCashPosition | 4.52M | 2.12M | 2.12M | 2.79M |
| EffectOfExchangeRateChanges | 40.34K | -259.68K | -214.55K | -154.14K |
| ChangesInCash | -1.67M | 2.66M | 209.49K | -509.63K |
| FinancingCashFlow | 144.97K | 6.27M | 108.17K | -28.22K |
| CashFlowFromContinuingFinancingActivities | 144.97K | 6.27M | 108.17K | -28.22K |
| NetOtherFinancingCharges | 144.97K | 6.27M | 150.00K | -1.92K |
| InterestPaidCFF | -8.88K | -7.79K | ||
| CashDividendsPaid | 0.00 | 0.00 | ||
| NetCommonStockIssuance | 150.00K | 0.00 | ||
| CommonStockIssuance | 150.00K | 0.00 | ||
| NetIssuancePaymentsOfDebt | 0.00 | -34.04K | -26.30K | |
| NetLongTermDebtIssuance | 0.00 | -34.04K | -26.30K | |
| LongTermDebtPayments | 0.00 | -34.04K | -26.30K | |
| InvestingCashFlow | 418.20K | -1.79M | -450.50K | -490.57K |
| CashFlowFromContinuingInvestingActivities | 418.20K | -1.79M | -450.50K | -490.57K |
| NetOtherInvestingChanges | 79.85K | |||
| DividendsReceivedCFI | 68.13K | 61.41K | 115.38K | 22.04K |
| NetInvestmentPurchaseAndSale | 497.21K | -1.71M | -511.71K | -509.45K |
| SaleOfInvestment | 1.07M | 26.15K | 0.00 | 6.39K |
| PurchaseOfInvestment | -571.57K | -1.73M | -511.71K | -515.84K |
| NetBusinessPurchaseAndSale | 0.00 | |||
| SaleOfBusiness | 0.00 | |||
| NetPPEPurchaseAndSale | -226.99K | -149.40K | -54.17K | -3.16K |
| SaleOfPPE | 0.00 | |||
| PurchaseOfPPE | -226.99K | -149.40K | -54.17K | -3.16K |
| OperatingCashFlow | -2.23M | -1.82M | 551.82K | 9.16K |
| CashFlowFromContinuingOperatingActivities | -2.23M | -1.82M | 551.82K | 9.16K |
| ChangeInWorkingCapital | 115.40K | 117.98K | 833.38K | -862.25K |
| ChangeInOtherWorkingCapital | 57.05K | -67.77K | -2.99K | 104.98K |
| ChangeInOtherCurrentLiabilities | -42.90K | 76.62K | -126.69K | -20.17K |
| ChangeInPayablesAndAccruedExpense | 204.34K | -381.29K | -119.69K | -1.18M |
| ChangeInPayable | 204.34K | -381.29K | -119.69K | -1.18M |
| ChangeInInventory | -250.85K | -160.39K | 544.11K | -345.75K |
| ChangeInReceivables | 147.76K | 650.81K | 538.65K | 579.22K |
| ChangesInAccountReceivables | 650.81K | 538.65K | 579.22K | |
| OtherNonCashItems | 30.92K | 8.88K | 7.79K | |
| StockBasedCompensation | 511.74K | 0.00 | ||
| UnrealizedGainLossOnInvestmentSecurities | -69.48K | -306.61K | 70.63K | 29.85K |
| ProvisionandWriteOffofAssets | -805.88K | 942.80K | 0.00 | |
| AssetImpairmentCharge | 46.52K | 12.90K | 5.94K | 3.81K |
| DepreciationAmortizationDepletion | 153.14K | 108.42K | 105.42K | 108.22K |
| DepreciationAndAmortization | 153.14K | 108.42K | 105.42K | 108.22K |
| Depreciation | 153.14K | 108.42K | 105.42K | 108.22K |
| OperatingGainsLosses | -106.54K | -68.65K | -115.38K | -22.04K |
| GainLossOnInvestmentSecurities | -106.54K | -68.65K | -115.38K | -22.04K |
| GainLossOnSaleOfPPE | 0.00 | |||
| NetIncomeFromContinuingOperations | -1.60M | -2.63M | -355.97K | 751.57K |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for BGLC
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|